Subtyping of non-small cell lung carcinoma: A comparison of small biopsy and cytology specimens

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1849-1856

  Sigel, Carlie S ^a   Moreira, Andre L ^a   Travis, William D ^a   Zakowski, Maureen F ^a   Thornton, Raymond H ^b   Riely, Gregory J ^a   Rekhtman, Natasha ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Interventional Radiology Service   (United States)

Author keywords

Adenocarcinoma; Biopsy; Cytology; Squamous cell carcinoma

Indexed keywords

PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; CANCER DIAGNOSIS; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KAPPA STATISTICS; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; TISSUE TYPING; TUMOR DIFFERENTIATION;

EID: 80054935174     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318227142d     Document Type: Article

References (48)

1. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-414.
2. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011;32:22-31.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
4. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008;21(Suppl 2):S16-S22. (Pubitemid 351592769)
5. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
6. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pem-etrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70.
7. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
8. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-1242.
9. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
10. Schrump DS, Altorki NK, Henschke CL, et al. Non-small cell lung cancer. In VT DeVita, S Hellman, SA Rosenberg (Eds.), Cancer: Principles and Practices of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2005. Pp. 753-810.
11. Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009;4:1202-1211.
12. Edwards SL, Roberts C, McKean ME, et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000;53:537-540. (Pubitemid 30432112)
13. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole tissue sections with validation in small specimens. Mod Pathol. [Epub ahead of print May 27, 2011] DOI: 10.1038/modpathol.2011.92.
14. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805-1811.
15. Rossi G, Papotti M, Barbareschi M, et al. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol 2009;27:e141- e142; author reply e143-e144.
16. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-441.
17. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, nap-sin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25.
18. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-447.
19. Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009;37:178-183.
20. Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011;6:1039-1049.
21. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610-619.
22. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. [Epub ahead of print January 18, 2011] DOI: 10.1002/cncr.25830.
23. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011;6:451-458.
24. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarci-noma. J Thorac Oncol 2011;6:244-285.
25. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363-374. (Pubitemid 8131514)
26. Aviram G, Greif J, Man A, et al. Diagnosis of intrathoracic lesions: are sequential fine-needle aspiration (FNA) and core needle biopsy (CNB) combined better than either investigation alone? Clin Radiol 2007;62: 221-226. (Pubitemid 46206716)
27. Yamagami T, Iida S, Kato T, et al. Combining fine-needle aspiration and core biopsy under CT fluoroscopy guidance: a better way to treat patients with lung nodules? AJR Am J Roentgenol 2003;180:811-815. (Pubitemid 36237234)
28. Matsuda M, Horai T, Nakamura S, et al. Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer. Thorax 1986;41:475-478. (Pubitemid 16089183)
29. Nizzoli R, Tiseo M, Gelsomino F, et al. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol 2011;6:489-493.
30. Thomas JS, Lamb D, Ashcroft T, et al. How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. Thorax 1993;48:1135-1139. (Pubitemid 23336832)
31. Suh J, Rekhtman N, Ladanyi M, et al. Testing of new IASLC/ATS/ERS criteria for diagnosis of lung adenocarcinoma (AD) in small biopsies: minimize immunohistochemistry (IHC) to maximize tissue for molecular studies. Mod Pathol 2011;24:404A-431A, 424A.
32. Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol 2003;30:3-8. (Pubitemid 36254670)
33. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010;134:1628-1638.
34. Bocking A, Klose KC, Kyll HJ, et al. Cytologic versus histologic evaluation of needle biopsy of the lung, hilum and mediastinum. Sensitivity, specificity and typing accuracy. Acta Cytol 1995;39:463-471.
35. Klein JS, Salomon G, Stewart EA. Transthoracic needle biopsy with a coaxially placed 20-gauge automated cutting needle: results in 122 patients. Radiology 1996;198:715-720. (Pubitemid 26066287)
36. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003;123:115S-128S. (Pubitemid 36135709)
37. Jones AM, Hanson IM, Armstrong GR, et al. Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy. Respir Med 2001;95:374-378. (Pubitemid 32624482)
38. Govert JA, Dodd LG, Kussin PS, et al. A prospective comparison of fiberoptic transbronchial needle aspiration and bronchial biopsy for bronchoscopically visible lung carcinoma. Cancer 1999;87:129-134. (Pubitemid 29289246)
39. Dobler CC, Crawford AB. Bronchoscopic diagnosis of endoscopically visible lung malignancies: should cytological examinations be carried out routinely? Intern Med J 2009;39:806-811.
40. Boiselle PM, Shepard JA, Mark EJ, et al. Routine addition of an automated biopsy device to fine-needle aspiration of the lung: a prospective assessment. AJR Am J Roentgenol 1997;169:661-666. (Pubitemid 27364967)
41. Yung RC. Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy. Respir Care Clin N Am 2003;9:51-76. (Pubitemid 36748364)
42. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007;2:1086-1090. (Pubitemid 350307900)
43. Horiike A, Kimura H, Nishio K, et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007;131:1628-1634. (Pubitemid 46981613)
44. Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009;117:67-72.
45. Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011;119:111-117.
46. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169-1180.
47. Solomon SB, Zakowski MF, Pao W, et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 2010;194:266-269.
48. Chandan VS, Zimmerman K, Baker P, et al. Usefulness of core roll preparations in immediate assessment of neoplastic lung lesions: comparison to conventional CT scan-guided lung fine-needle aspiration cytology. Chest 2004;126:739-743. (Pubitemid 39258025)